NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»24/08/2009 [Industry news]
Lundbeck appoints new manager in China

Lundbeck has appointed Oscar Parra, who most recently held the position as product manager with the Group, as new country manager of Lundbeck subsidiary in China.

 
Lundbeck appoints new manager in China Lundbeck has appointed Oscar Parra, who most recently held the position as product manager with the Group, as new country manager of Lundbeck subsidiary in China. In China, 36-year-old Oscar Parra will be responsible for continuing and consolidating Lundbecks positive performance in the country in recent years. He will also be in charge of Lundbeck Hong Kong. Oscar Parra joined Lundbeck from German pharmaceuticals group Fresenius Kabi in 2001 and has been one of the key contributors to the highly successful marketing and proliferation of the anti-Alzheimer agent Ebixa, which is now Lundbeck\'s second-best selling pharmaceutical, generating revenue of DKK 1.9bn in 2008. Oscar Parra was in charge of launching Ebixa in Mexico, the first country in which Lundbeck marketed the pharmaceutical. Since then, he has been involved in launching the product in the remaining 58 countries around the world where Ebixa is currently available. In his capacity as international brand manager and subsequently product manager, Oscar Parra also had overall responsibility for the strategic marketing of Ebixa, for the anti-Parkinson agent Azilect and the sleep agent Circadin. Moreover, he was in charge of Lundbeck\'s strategic alliances with the companies with which Lundbeck markets the above-mentioned drugs. Consequently, Oscar Parra has in-depth knowledge about Ebixa, which is an important product for Lundbeck\'s operations in China, holding a market share of 16%. \"During his eight years with Lundbeck, Oscar has demonstrated great skill in terms of maximising the commercial return on our products. His skills are exactly what we need in our efforts to expand Lundbeck\'s operations in China, so I\'m very pleased that Oscar has accepted this challenge,\" said Stig L鴎ke Pedersen, Executive Vice President, Commercial Operations. The move to China will bring Oscar Parra to the third country of his Lundbeck career. He was born in Mexico and started in Lundbeck\'s Mexican subsidiary before moving to the corporate headquarters in Denmark in 2002. He will now travel to a whole different part of the world. \"The opportunity to work at different locations around the world was one of the reasons why I originally applied for a position with a global company such as Lundbeck. I\'m very happy with the opportunities and challenges I have been given so far and very much look forward to the exciting work in China,\" said Oscar Parra.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.